Wei Y, Ji XB, Wang YW, et al.High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia:aprospective multicenter randomized trial[J].Blood, 2016, 127:296-302.

Wong RSM, Saleh MN, Khelif A, et al.Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag:final results of the EXTEND study[J].Blood, 2017, 130:2527-2536.

Bussel JB, Kuter DJ, Pullarkat V, et al.Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP[J].Blood, 2009, 113:2161-2171.

Kuter DJ, Bussel JB, Newland A, et al.Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia:safety and efficacy[J].Br J Haematol, 2013, 161:411-423.

Zhang J, Liang Y, Ai Y, et al.Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia:a systematic review incorporating an indirect-comparison meta-analysis[J].Sci Rep, 2018, 8:576.

Khellaf M, Charles-Nelson A, Fain O, et al.Safety and efficacy of rituximab in adult immune thrombocytopenia:results from a prospective registry including 248patients[J].Blood, 2014, 124:3228-3236.

Patel VL, Mahévas M, Lee SY, et al.Outcomes 5years after response to rituximab therapy in children and adults with immune thrombocytopenia[J].Blood, 2012, 119:5989-5995.

Vianelli N, Palandri F, Polverelli N, et al.Splenectomy as a curative treatment for immune thrombocytopenia:a retrospective analysis of 233 patients with a minimum follow up of 10years[J].Haematologica, 2013, 98:875-880.